Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus

Jing He, Xia Zhang, Yunbo Wei, Xiaolin Sun, Yaping Chen, Jun Deng, Yuebo Jin, Yuzhou Gan, Xin Hu, Rulin Jia, Chuanhui Xu, Zhaohua Hou, Yew Ann Leong, Lei Zhu, Jinhong Feng, Yuan An, Yuan Jia, Chun Li, Xu Liu, Hua YeLimin Ren, Ru Li, Haihong Yao, Yuhui Li, Shi Chen, Xuewu Zhang, Yin Su, Jianping Guo, Nan Shen, Eric F Morand, Di Yu, Zhanguo Li

Research output: Contribution to journalArticleResearchpeer-review

210 Citations (Scopus)


Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease characterized by altered balance of activity between effector and regulatory CD4+ T cells. The homeostasis of CD4+ T cell subsets is regulated by interleukin (IL)-2, and reduced production of IL-2 by T cells is observed in individuals with SLE. Here we report that treatment with low-dose recombinant human IL-2 selectively modulated the abundance of regulatory T (Treg) cells, follicular helper T (TFH) cells and IL-17-producing helper T (TH17) cells, but not TH1 or TH2 cells, accompanied by marked reductions of disease activity in patients with SLE.

Original languageEnglish
Pages (from-to)991-993
Number of pages3
JournalNature Medicine
Issue number9
Publication statusPublished - Sep 2016


  • autoimmunity
  • regulatory T cells
  • systemic lupus erythematosus

Cite this